A small pharmaceutical company in New Jersey is diligently working with the FDA on our behalf to start a first-ever Clear Cell Sarcoma combination drug trial. This collaboration was patient initiated and is patient driven. Sara’s Cure has been asked to help with the travel portion of this trial. Will you help a family by supporting travel expenses to a treatment? Click here
A Patient Registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure and that serves predetermined scientific, clinical, or policy purpose(s). We at Sara’s Cure have officially initiated our patient registry in January, 2020. NORD (National Organization for Rare Disorders) owns the registry platform. We are also in partnership with NORD establishing a first-ever national history study. Click here
Dr. Andrea Hayes-Jordan has offered to join our cause to research for a cure for Clear Cell Sarcoma (CCS). The Hayes-Jordan lab will use single cell sequencing to precisely identify the genes that make CCS tumors grow and spread. We need to raise $50,000 dollars to begin funding this project.
The most pressing issue is identification of a beneficial treatment for Clear Cell Sarcoma. In this regard we are funding an organization that collects our patient tissue from biopsy or surgery and sends it to The Broad Institute of MIT and Harvard where they will grow cell and mouse models for repurposed drug testing. We need another $350,000 to complete the repurposed drug testing project over the next 2 years. This will not only benefit Clear Cell Sarcoma patients, but it will benefit all Sarcoma patients for years to come. Click here